Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Supports overall health and energy levels
SURPASS-2: The Only Head-to-Head Trial The SURPASS-2 trial (NEJM, 2021) is the most important study in this comparison because it directly tested tirzepatide against semaglutide in 1,879 patients with type 2 diabetes over 40 weeks
It activates the Nrf2 pathway, a master regulator that upregulates multiple antioxidant enzymes simultaneously, creating a comprehensive antioxidant response
Moving beyond food noise to drug noise, GLP-1s are quieting the roar of addiction.
Determinants of the impaired secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetic patients
US$ 26.25
US$ 23.78
US$ 29.15
US$ 29.27
